About Oncimmune

Oncimmune operates the world's most comprehensive antibody biomarker discovery platform, ImmunoINSIGHTS™, which profiles the immune system's response to disease. The proprietary technology interrogates more than 9000 human antigens using minimal sample volumes, combining high throughput immunoassays with bioinformatics to identify autoantibody signatures across immuno-oncology, autoimmune diseases, and infectious diseases. The platform supports pharmaceutical companies, biotechnology firms, and academic groups in developing more effective, targeted, and safer treatments. Through automated workflows and multiomics data integration, it delivers rapid, reproducible results enabling earlier disease detection and accelerated drug development.